MET molecular mechanisms and therapies in lung cancer

Cell Adhesion and Migration

Volumn 4, Issue 1, 2010, Pages 146-152

  Lawrence, Ryan E ^a   Salgia, Ravi ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Hepatocyte growth factor; Lung cancer; MET; Paxillin; Tyrosine kinase

Indexed keywords

CYTOSKELETON PROTEIN; GELDANAMYCIN; MET ENZYME; PAXILLIN; PROTEIN TYROSINE KINASE; SCATTER FACTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL GROWTH; CELL MOTILITY; CELL PROLIFERATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; MITOSIS; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UPREGULATION;

EID: 77449141050     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/cam.4.1.10973     Document Type: Review

References (54)

1. Fell JW. A treatise on cancer, and its treatments. London: John Churchill, New Burlington Street 1857.
2. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 1984; 311:29-33.
3. Dean M, Park M, LeBeau MM, Robins TS, Diaz MO, Rowley JD, et al. The human met oncogene is related to the tyrosine kinase oncogenes. Nature 1985; 315:385-8.
4. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 1993; 123:223-35.
5. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto Narsimhan CRP, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO Journal 1991; 10:2867-78.
6. Kim ES, Salgia R. MET pathway as a therapeutic target. J Thoracic Oncol 2009; 4:444-7.
7. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (London) 1987; 327:239-42.
8. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer and Metastasis Reviews 2003; 22:209-325.
9. Ma PC, Tretiakova MS, Mackinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes, Chromosomes & Cancer 2008; 47:1025-37.
10. Rong S, Segal S, Anver M, Resau JH, VandeWoude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Nati Acad Sci 1994; 91:4731-5.
11. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine & Growth Factor Reviews 2002; 13:41-59.
12. Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase met. Cancer Treat Res 2004; 119:121-38.
13. Maulik G, Madhiwala P, Brooks S, Ma PC, Kijima T, Tibaldi EV, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002; 6:539-53.
14. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Research 2003; 63:6272-81.
15. Ponzetto C, Bardelli A, Zhen Z, Maina F, della Zonca P, Giordano S, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994; 77:261-71.
16. Besser D, Bardelli A, Didichenko S, Thelen M, Comoglio PM, Ponzetto C, et al. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2. Oncogene 1997; 14:705-11.
17. Wojta J, Nakamura T, Fabry A, Hufnagl P, Beckmann R, McGrath K, et al. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor type 1 and tissue factor in HepG2 cells. Blood 1994; 84:151-7.
18. Dunsmore SE, Rubin JS, Kovacs SO, Chedid M, Parks WC, Welgus HG. Mechanisms of hepatocyte growth factor stimulation of keratinocyte metalloproteinase production. J Biol Chem 1996; 271:24576-82.
19. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992; 119:629-41.
20. Olivero M, Rizzo M, Madeddu R, Casadio C, Pennacchietti S, Nicotra MR, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996; 74:1862-8.
21. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in Non-small cell lung cancer. Cancer Research 2005; 65:1479-88.
22. Kanteti R, Yala S, Furguson MK, Salgia R. MET HGF, EGFR and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples, and prognostic significance. J Environ Pathol Toxicol Oncol 2009; 28:89-98.
23. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clinical Cancer Research 2009; 15:5714-23.
24. Salgia R, Li JL, Ewaniuk D, Wang YB, Sattler M, Chen WC, et al. Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility. Oncogene 1999; 18:67-77.
25. Sattler M, Pride YB, Ma PC, Gramlich JL, Chu SC, Quinnan LA, et al. A novel small molecule Met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Research 2003; 63:5462-9.
26. Maulik G, Kijima T, Ma PC, Ghosh SK, Lin G, Shapiro GI, et al. Modulation of the c-met/hepatocyte growth factor pathway in small cell lung cancer. Clinical Cancer Research 2002; 8:620-7.
27. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon AC, Seiwert TY, et al. Paxillin is a target for somatic mutations in lung cancer: Implications for cell growth and invasion. Cancer Research 2008; 68:132-42.
28. Pallier K, Houllier AM, Cazes A, Laurent-Puig P, Blons H. No somatic genetic change in the paxillin gene in nonsmall-cell lung cancer. Mol Carcinog 2009; 48:581-5.
29. Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, et al. Downregulation of Micro-Rna-1 (miR-1) in lung cancer: suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 2008; 283:33394-405.
30. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36:305-15.
31. Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res 2006; 12:6087-93.
32. Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 2000; 70:1853-60.
33. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23:1078-87.
34. Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, et al. An uncleavable form of proscatter factor suppresses tumor growth and dissemination in mice. J Clin Invest 2004; 114:1418-32.
35. Otsuka T, Jakabczak J, Vieira W, Bottaro DP, Breckenridge D, Larochelle WJ, et al. Disassociation of met-mediated biological responses in vivo: the natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis. Mol Cell Biol 2000; 20:2055-65.
36. Sakai K, Nakamura T, Matsumoto K, Nakamura T. Angioinhibitory action of NK4 involves impaired extra-cellular assembly of fibronectin mediated by perlecan-NK4 association. J Biol Chem 2009; 284:22491-9.
37. Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, et al. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood 2007; 109:3042-9.
38. Buhles A, Collins SA, van Pijkeren JP, Rajendran S, Miles M, O'Sullivan GC, et al. Anti-metastatic effects of viral and non-viral mediated Nk4 delivery to tumours. Genet Vaccines Ther 2009; 7.
39. Michieli P, Mazzone M, Basilico C, Cavassa S, Sottile A, Naldini L, et al. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell 2004; 6:61-73.
40. Kakkar T, Ma M, Zhuang Y, Patton A, Hu Z, Mounho B. Pharmacokinetics and safety of a fully human hepatocyte growth factor antibody, AMG 102, in cynomolgus monkeys. Pharm Res 2007; 24:1910-8.
41. Jun HT, Sun J, Rex K, Radinsky R, Kendall R, Coxon A, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res 2007; 13:6735-42.
42. Cassinelli G, Lanzi C, Petrangolini G, Tortoreto M, Pratesi G, Cuccuru G, et al. Inhibition of c-Met and prevention of spontaneous metastatic spreading by the 2-indolinone RPI-1. Mol Cancer Ther 2006; 5:2388-97.
43. Morotti A, Mila S, Accornero P, Tagliabue E, Ponzetto C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 2002; 21:4885-93.
44. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET inhibitor, PHA665752, cooperates with rapamycin. Clinical Cancer Research 2005; 11:2312-9.
45. Puri N, Khramtsov A, Salman A, Nallasura V, Hetzel JT, Jagadeeswaran R, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Research 2007; 67:3529-34.
46. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Research 2007; 67:4408-17.
47. McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Research 2008; 68:3389-95.
48. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res 2009; 69:8009.
49. Sugawara M, Geffner DL, Martinez D, Hershman JM. Novel treatment of medullary thyroid cancer. Curr Opin Endocrinol Diabetes Obes 2009; 16:367-72.
50. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, et al. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol Cancer Ther 2009; 8:1-10.
51. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to Gefitinib resistance in lung cancer by activating ERBB3 Signaling. Science 2007; 316:1039-43.
52. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104:20932-7.
53. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2009; In press.
54. Siddiqui S, Loganathan S, Krishnaswamy S, Faoro L, Jagadeeswaran R, Salgia R. C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes. Cancer Biol Ther 2008; 7:856-63.